Our Process

Arrivo has two clinical-stage pipeline candidates, SP-624 for major depressive disorder and RABI-767 for predicted severe acute pancreatitis, each featuring new mechanisms of action, and each designed to offer novel treatment options for patients suffering from diseases and disorders that continue to have high unmet medical need.